Search
Now showing items 331-340 of 591
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life.
(SPRINGERNATURE, 2021-02-18)
Treatment options in multiple myeloma (MM) are increasing with the introduction of complex multi-novel-agent-based regimens investigated in randomized clinical trials. However, application in the real-world setting, including ...
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
(SPRINGERNATURE, 2021-03-02)
BACKGROUND: Schlafen 11 (SLFN11) has been linked with response to DNA-damaging agents (DDA) and PARP inhibitors. An in-depth understanding of several aspects of its role as a biomarker in cancer is missing, as is a ...
Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer.
(WILEY, 2021-02-25)
Analysis of the genomic landscape of prostate cancer has identified different molecular subgroups with relevance for novel or existing targeted therapies. The recent approvals of the poly(ADP-ribose) polymerase (PARP) ...
Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis.
(ELSEVIER, 2021-07-01)
BACKGROUND & AIMS: Checkpoint inhibitor-related hepatitis (CPI-Hep) is an emerging clinical challenge. We aimed to gain insights into the immunopathology of CPI-Hep by comprehensively characterising myeloid and lymphoid ...
Unmasking the immune microecology of ductal carcinoma in situ with deep learning.
(NATURE PORTFOLIO, 2021-03-01)
Despite increasing evidence supporting the clinical relevance of tumour infiltrating lymphocytes (TILs) in invasive breast cancer, TIL spatial variability within ductal carcinoma in situ (DCIS) samples and its association ...
An Inter-observer Study to Determine Radiotherapy Planning Target Volumes for Recurrent Gynaecological Cancer Comparing Magnetic Resonance Imaging Only With Computed Tomography-Magnetic Resonance Imaging.
(ELSEVIER SCIENCE LONDON, 2021-02-24)
AIMS: Target delineation uncertainty is arguably the largest source of geometric uncertainty in radiotherapy. Several factors can affect it, including the imaging modality used for delineation. It is accounted for by ...
RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease.
(AMER ASSOC CANCER RESEARCH, 2021-09-01)
Loss of the retinoblastoma (RB) tumor suppressor protein is a critical step in reprogramming biological networks that drive cancer progression, although mechanistic insight has been largely limited to the impact of RB loss ...
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.
(ELSEVIER, 2021-04-27)
Cell surface expression levels of GPRC5D, an orphan G protein-coupled receptor, are significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or other immune cells, which renders it a promising ...
Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs.
(NATL ACAD SCIENCES, 2021-04-27)
Cancer cells can survive chemotherapy-induced stress, but how they recover from it is not known. Using a temporal multiomics approach, we delineate the global mechanisms of proteotoxic stress resolution in multiple myeloma ...
Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry.
(ELSEVIER, 2021-06-15)
Soft tissue sarcomas (STS) are a group of rare and heterogeneous cancers. While large-scale genomic and epigenomic profiling of STS have been undertaken, proteomic analysis has thus far been limited. Here we utilise ...